Future work will focus on testing Serp-1 in complex wounds with comorbidities (e.g., infection, diabetes, burns), delineation of the molecular mechanism associated with Serp-1 therapeutic function (e.g., induction of cytokines and chemokines in the wound bed), and defining the mechanism of uPAR-dependent efficacy. This evidence concerns the gene SERP1 and diabetes mellitus.